BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DA-302168S readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of DA-302168S\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07938515-225@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20261212
DTEND;VALUE=DATE:20261213
SUMMARY:DA-302168S: Phase 1 readout est. (NCT07938515)
DESCRIPTION:DA-302168S\, phase 1\, Obesity.\nStudy: Pharmacokinetics\, Safe
 ty\, and Tolerability of DA-302168S Tablets in Participants With Varying D
 egrees of Renal Impairment and Normal Renal Function\nEstimated primary co
 mpletion: 12 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/da-302168s#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07938515
URL:https://assetmemo.bio/drug/da-302168s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07857265-225@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:DA-302168S: Phase 1 readout est. (NCT07857265)
DESCRIPTION:DA-302168S\, phase 1.\nStudy: Mass Balance Study of [14C]DA-302
 168S in Healthy Chinese Adult Male Participants\nEstimated primary complet
 ion: 20 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/da-302168s#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07857265
URL:https://assetmemo.bio/drug/da-302168s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07877038-225@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:DA-302168S: Phase 1 readout est. (NCT07877038)
DESCRIPTION:DA-302168S\, phase 1\, Obesity.\nStudy: Pharmacokinetics\, Safe
 ty\, and Tolerability of DA-302168S Tablets in Participants With Hepatic I
 mpairment and Normal Hepatic Function\nEstimated primary completion: 7 Apr
 il 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/da-302168s#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07877
 038
URL:https://assetmemo.bio/drug/da-302168s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07629544-225@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:DA-302168S: Phase 3 readout est. (NCT07629544)
DESCRIPTION:DA-302168S\, phase 3\, Obesity.\nStudy: A Study of DA-302168S i
 n Participants With Overweight/Obesity\nEstimated primary completion: 9 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/da-302168s#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07629
 544
URL:https://assetmemo.bio/drug/da-302168s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755150-225@assetmemo.bio
DTSTAMP:20261121T005848Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:DA-302168S: Phase 2 readout est. (NCT07755150)
DESCRIPTION:DA-302168S\, phase 2\, Type 2 Diabetes.\nStudy: A Study to Eval
 uate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2
  Diabetes\nEstimated primary completion: 20 October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/da-302168s#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07755150
URL:https://assetmemo.bio/drug/da-302168s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
